Announcement • Jan 05
SQZ Biotechnologies Files Form 15 SQZ Biotechnologies Company has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001 per share. Announcement • Nov 10
SQZ Biotechnologies Company Contemplates Bankruptcy. SQZ Biotechnologies Company is contemplating filing for bankruptcy, as of November 8, 2023. According to company SEC filing, the company has entered a restructuring plan whereby it proposes to reduce additional 80% of its employees, cease substantially all research and development activities to reduce ongoing operating expenses while the company pursue strategic alternatives which may include a sale of the Company or some or all of its assets by the end of 2023. The company is also looking for various alternatives whereby the company anticipate using available net proceeds to discharge liabilities and outstanding obligations. If the company is unable to identify and implement a meaningful strategic alternative in a timely manner, the Board of Directors are likely to consider bankruptcy or other dissolution proceedings. Announcement • Nov 04
SQZ Biotechnologies Reports Data for Clinical Programs at the Society for Immunotherapy of Cancer Annual Meeting SQZ Biotechnologies Company presented clinical data for three programs focused on the treatment of Human Papillomavirus 16 positive (HB16+) driven cancers at the Society for Immunotherapy of Cancer Annual Meeting 2023. Key findings: SQZ® Activating Antigen Carriers (“AAC”) Platform in Oncology: Poster# 693: SQZ-AAC-HPV-101: Initial data from a phase I dose escalation/expansion study of SQZ-AAC-HPV, a red blood cell-based therapeutic cancer vaccine for HPV16+ solid tumors: Of the five patients treated, one patient experienced a confirmed complete response and two patients experienced stable disease; SQZ-AAC-HPV monotherapy is considered generally safe and well-tolerated at all dose levels. SQZ® Enhanced Antigen Presenting Cell (“eAPC”) Platform in Oncology: Poster# 692: COMMANDER-001: Safety data from a phase I/II dose escalation/expansion study of SQZ-eAPC-HPV, a cell-based mRNA therapeutic cancer vaccine for HPV16+ solid tumors: Completed enrollment for highest-dose cohort of monotherapy dose escalation trial; Observed BOR of Stable Disease in 40% (8 of 20) of Treated Patients; SQZ-eAPC-HPV monotherapy is considered generally safe and well-tolerated at all dose levels. SQZ® Antigen Presenting Cell (“APC”) Platform in Oncology: Poster# 594: SQZ-PBMC-HPV-101: Increased overall survival in a subset of patients with recurrent, locally advanced, or metastatic HPV16+ tumors treated with cell-based vaccine, SQZ-PBMC-HPV: A subset of patients with paired biopsies (6 of 18) showed increased CD8 T cell infiltration when compared to baseline: These patients with increased CD8 T cell infiltration demonstrated an improved overall survival (“OS”) when compared to patients with decreased CD8 T cell infiltration; Median OS (95% CI) for Increase in CD8: 606.5 days (314.0, 713.0) compared to median OS (95% CI) for Decrease in CD8: 170.0 days (54.0, 220.0); SQZ-PBMC-HPV monotherapy is considered generally safe and well-tolerated at all dose levels. Human papillomavirus (HPV) is one of the most common viruses worldwide and certain strains persist for many years, often leading to cancer. According to the Centers for Disease Control (CDC), in the United States HPV+ tumors represent 3% of all cancers in women and 2% of all cancers in men, resulting in over 39,000 new cases of HPV+ tumors every year. HPV infection is larger outside of the U.S., and according to the International Journal of Cancer, HPV+ tumors account for 4.5% of all cancers worldwide resulting in approximately 630,000 new cases every year. According to the CDC, HPV infection plays a significant role in the formation of more than 90% of anal and cervical cancers, and most cases of vaginal (75%), oropharyngeal (70%), vulval (70%) and penile (60%) cancers. 
